Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Completed · Phase 3

Conditions studied: Peanut Allergy

In brief

The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.

Key facts

Study ID
NCT03292484
Run by
Aimmune Therapeutics, Inc.
People needed
911
Starts
2017-11-02
Expected to finish
2023-04-27
Last updated by the study team
2024-12-19

Who can join

Age: 1 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.